Journal article

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma

J Lewin, KK Khamly, RJ Young, C Mitchell, RJ Hicks, GC Toner, SYK Ngan, S Chander, GJ Powell, A Herschtal, L Te Marvelde, J Desai, PFM Choong, SA Stacker, MG Achen, N Ferris, S Fox, J Slavin, DM Thomas

British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2014

Grants

Funding Acknowledgements

JL received travel, accommodations, and expenses from Bayer; Relationship: You. RJH received honoraria from Novartis, Relationship: You; played a consulting or advisory role in Pfizer, Novartis, and Bayer, Relationship: Your Institution; received research funding from Pfizer, Novartis, Roche/Genentech, Amgen, and Bristol-Myers Squibb, Relationship: Your Institution; GCT played a consulting or advisory role in Ipsen, Bayerm, and Pfizer, Relationship: Your Institution; received research funding from Bayer, Bristol-Myers Squibb, Medivation from Company, Relationship: Your Institution. JD played a consulting or advisory role in Merck Serono, Novartis, Bayer, BiPar/sanofi-aventis, Bionomics, Vegenics, and GlaxoSmithKline, Relationship: You; received Research Funding from Novartis, GlaxoSmithKline, and Roche. Relationship: You; PFMC played a consulting or advisory role, in Johnson & Johnson, Relationship: You; received travel, accommodations, expenses from Johnson & Johnson, Relationship: You; SAS had stock or other ownership in Circadian Technologies, Ark Therapeutics, and Sonic healthcare, Relationship: You; played a consulting or advisory role in Circadian Technologies, Relationship: You; received patents, royalties, and other intellectual property from Circadian Technologies and Ark Therapeutics. MGA had stock or other ownership in Circadian Technologies and Ark Therapeutics, Relationship: You; played a consulting or advisory role in Circadian Technologies, Relationship: You; received patents, royalties, and other intellectual property from Circadian Technologies and Ark Therapeutics; DT received research funding from Pfizer, Relationship: Your Institution.